

Introduction to LEO Pharma's **Open Innovation** platform

This is a one-page executive summary highlighting the key points of LEO Pharma Open Innovation. LEO Pharma is a foundation-owned pharmaceutical company focusing on dermatology and skin inflammation, having a well-established product portfolio.

LEO Pharma is interested in exploring new opportunities and ways of working with external research partners. To achieve this LEO Pharma has established Open Innovation as a collaborative initiative where unique research tools are made available for external partners.

What we offer you:

- ✓ **Free testing** of molecules in disease-relevant, cell based in vitro assays
- ✓ Description of the assays used and the science behind (see other side of this page)
- ✓ Structural confidentiality – your compound's structure does not have to be disclosed
- ✓ **No business terms** – Partner is in control and can walk away at any time
- ✓ **Partner owns generated data** - LEO Pharma studies it to evaluate scientific interest

Jointly we would like to:

- Identify new molecules that can be used in hit, lead, or late stage drug discovery
- Explore new pathways and targets by use of pharmacological tool compounds
- Engage in an open dialogue about business potential based on collaborative science
- Make it much easier to work with Biotechs, Pharma, Startups and Universities

Please find more information at the web portal: <http://openinnovation.leo-pharma.com>

We are delighted to offer the Open Innovation platform and invite you to join our mission and explore new ways of collaborating to bring innovative treatments to patients!

On behalf of LEO Pharma Research,

Niclas Nilsson, MSc PhD
Head of Open Innovation


and

Jakob Felding, PhD
Director of Skin Research

Any questions? Please contact: open.innovation@leo-pharma.com




The science and R&D tools we offer




Psoriatic inflammation in human keratinocytes

Human primary keratinocytes are stimulated using a psoriasis-specific cytokine cocktail that induces an inflammatory response measured as an increase in IL-8 secretion. Your molecules are tested for their ability to inhibit this inflammatory response. General cell viability is also measured.




Eczematous inflammation in human keratinocytes

Human primary keratinocytes are stimulated using an eczema-specific cytokine cocktail that induces an inflammatory response measured as an increase in CCL2 secretion. Your molecules are tested for their ability to inhibit this inflammatory response as well as cell viability.



IL-2 and IL-4 release from primary human CD4+ T cells

Purified human primary CD4+ T cells are stimulated to produce the eczema relevant cytokines IL-2 and IL-4. Your compounds are tested for their ability to inhibit this inflammatory response, as well as for any general effect on cell proliferation.



IL-17 release from primary human PBMCs

Human primary PBMC (Peripheral Blood Mononuclear Cells) are activated by a CD3, CD28, and IL-23 cocktail, resulting in increased production of IL-17. Your compounds are tested for the ability to inhibit the IL-17 release. A secondary viability readout is also provided.

What's the next step...

Simply download the minimal and specific open innovation agreement from the web portal and complete it. We will counter-sign it and send you empty vials. We request 200 uL of your compound at a concentration of 1-10 mM in DMSO. We look forward to testing your molecules for disease-relevant activity and exploring science together!

<http://openinnovation.leo-pharma.com>

LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in over 100 countries around the world, we help people manage their skin disease. Founded in 1908 and owned by the LEO Foundation, we have devoted decades of research and development to delivering products and solutions to people with skin diseases. With no external stakeholders, we are first and foremost accountable to patients, and we can commit to long-term innovation.

Today we are a fully integrated global healthcare company offering treatments for psoriasis, eczema, actinic keratosis, acne and skin infections.

We want to help more patients, so we are strengthening our portfolio and pipeline through external partnerships and innovation.

In the future, we want to expand our portfolio to include both topical and systemic treatments in a wider range of dermatology indications. Together with our partners, we strive to be the leading experts in skin.